The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells
Authors:
Open Access
- 12 August 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1443704
Abstract
Introduction: The Janus kinase (JAK) family includes four cytoplasmic tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) constitutively bound to several cytokine receptors. JAKs phosphorylate downstream signal transducers and activators of transcription (STAT). JAK-STAT5 pathways play a critical role in basophil and mast cell activation. Previous studies have demonstrated that inhibitors of JAK-STAT pathway blocked the activation of mast cells and basophils.Methods: In this study, we investigated the in vitro effects of ruxolitinib, a JAK1/2 inhibitor, on IgE- and IL-3-mediated release of mediators from human basophils, as well as substance P-induced mediator release from skin mast cells (HSMCs).Results: Ruxolitinib concentration-dependently inhibited IgE-mediated release of preformed (histamine) and de novo synthesized mediators (leukotriene C4) from human basophils. Ruxolitinib also inhibited anti-IgE- and IL-3-mediated cytokine (IL-4 and IL-13) release from basophils, as well as the secretion of preformed mediators (histamine, tryptase, and chymase) from substance P-activated HSMCs.Discussion: These results indicate that ruxolitinib, inhibiting the release of several mediators from human basophils and mast cells, is a potential candidate for the treatment of inflammatory disorders.Keywords
This publication has 113 references indexed in Scilit:
- Ruxolitinib inhibits poly(I:C) and type 2 cytokines‐induced CCL5 production in bronchial epithelial cells: A potential therapeutic agent for severe eosinophilic asthmaImmunity, Inflammation and Disease, 2021
- Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitorsMedical Oncology, 2018
- Tryptase as a polyfunctional component of mast cellsHistochemistry and Cell Biology, 2018
- Neuropeptide substance P and the immune responseCellular and Molecular Life Sciences, 2016
- Isolation of Human BasophilsCurrent Protocols in Immunology, 2016
- IgE and IL‐33−mediated triggering of human basophils inhibits TLR4−induced monocyte activationEuropean Journal of Immunology, 2014
- STAT5 in human basophils: IL‐3 is required for its FcεRI‐mediated phosphorylationCytometry Part B: Clinical Cytometry, 2011
- IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activationInflammation Research, 2009
- The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)Cancer, 2006
- Purified human peripheral blood basophils release interleukin‐13 and preformed interleukin‐4 following immunological activationEuropean Journal of Immunology, 1996